Gilead Sciences, Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US3755581036
USD
122.62
-1.29 (-1.04%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Gilead Sciences, Inc. stock-summary
stock-summary
Gilead Sciences, Inc.
Pharmaceuticals & Biotechnology
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
Company Coordinates stock-summary
Company Details
333 LAKESIDE DR , FOSTER CITY CA : 94404
stock-summary
Tel: 1 650 5743000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 219 Schemes (42.51%)

Foreign Institutions

Held by 579 Foreign Institutions (20.4%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Daniel O'Day
Chairman of the Board, Chief Executive Officer
Mr. Kevin Lofton
Lead Independent Director
Dr. Jeffrey Bluestone
Director
Mr. Javier Rodriguez
Director
Mr. Anthony Welters
Director
Dr. Jacqueline Barton
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
7,063 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,960 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 143,785 Million (Large Cap)

stock-summary
P/E

15.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.70%

stock-summary
Debt Equity

0.94

stock-summary
Return on Equity

47.06%

stock-summary
Price to Book

7.31